Biphasic activation of complement and fibrinolysis during the human nasal allergic response - 04/05/18
This work was supported by funding from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the NIHR BRC at Guy's and St Thomas’ NHS Foundation Trust and King's College London, the NIHR Health Protection Research Unit in Respiratory Infections at Imperial College London in partnership with Public Health England, the NIHR Imperial Patient Safety Translational Research Centre, and the British Heart Foundation (grant no. FS/12/60/28974). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health. E.H.M. was supported by a Medical Research Council (MRC)-funded PhD studentship within the MRC and Asthma UK Centre for Allergic Mechanisms of Asthma. |
|
Disclosure of potential conflict of interest: R. S. Thwaites’ institution has received grant funding from the National Institute for Health Research (NIHR)-Imperial BRC, NIHR-Health Protection Research Unit (HPRU), and NIHR-Imperial Patient Safety Translational Research Centre (IPSTRC). The Biochemical Society has provided travel grant funding to his institution. N. C. Gunawardana's institution has received funding from an Imperial NIHR-BRC grant and from Merck & Co for unrelated work. J. Ahnström's institution has received grant funding (grant no. FS/12/60/29874) to support a research fellowship from the British Heart Foundation for the author and for other projects unrelated to this work. G. A. Campbell, S. Lindsley, and N. Singh's institutions have received grant funding from the NIHR-BRC. T. Tunstall's institution has received grant funding and travel support from the NIHR-BRC. D. A. Lane received fees for expert testimony from NovNordisk, and his institution has grant funding pending from the British Heart Foundation and the Medical Research Council. P. J. Openshaw's institution has received grant funding from the NIHR-BRC, NIHR-HPRU, and the British Heart Foundation (grant no. FS/12/60/28974) and has grants pending from the Human Infection Challenge-Vaccine (HIC-Vac) Network, Respiratory Syncytial Virus Consortium in Europe (RESCEU), BMRC (grant no. BRC-1215-20013), the Medical Research Council/GlaxoSmith Kline-EMINENT Network, the Wellcome Trust Translation Fund (grant no. P57603/4), and NIHR Senior Investigator award. He has received fees for the development of educational presentations from the European Respiratory Society, and consultancy fees from Janssen Vaccines & Prevention B.V. and Bavarian Nordic, Inc. Travel accommodations have been paid for by international travel. T. T. Hansel has received consultant fees not related to this submission from h-VIVO and Genentech. His institution has received grant funding from the NIHR-BRC. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 5
P. 1892 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?